You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.

Enter your Email address:

Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.

Decreased Prostate Cancer Risk Found Again with Selenium

WASHINGTON—Depending on the study, selenium either shows an associated reduced risk of prostate cancer, or it doesn't. Now, researchers in the Netherlands, where men typically have low selenium levels, reported that selenium is associated with a substantial decrease in the risk of advanced prostate cancer, particularly during later follow-up.

The trial, reported here at the American Association for Cancer Research Annual Meeting (Abstract 3613) is unique in that the researchers studied toenail selenium, which they say reflects longer exposure to selenium.

“Studies in the past have been conducted among men with moderate to high selenium levels, but it is important to study populations of men who have low to moderate levels of selenium, who would be expected to have a higher risk of prostate cancer,” said the first author, Milan S. Geybels, a PhD candidate in Cancer Epidemiology at the CAPHRI School for Public Health of Maastricht University in the Netherlands.

Also, he said, studies in the past have used plasma or serum selenium, which reflect recent selenium intake versus long-term exposure.

Part of Netherlands Cohort Study of 58,279 Men

The new study was part of the Netherlands Cohort study of 58,279 men, age 55 to 69. The selenium study population included 898 men identified as having advanced prostate cancer (Stages III/IV) during a 17-year follow-up, and 1,203 men in a subcohort. Toenail clippings were submitted by participants in the study by mail when they returned the questionnaires to enroll.

The average toenail selenium concentration in the subcohort was 0.549 μg/g. Men who developed advanced prostate cancer had lower concentrations, averaging 0.527 μg/g. Those with the highest amount of toenail selenium had a 59 percent reduction in the risk of developing advanced prostate cancer.

“We specifically evaluated advanced prostate cancer because that is associated with a poor prognosis and therefore clinically relevant,” he said.

Important Biological Functions

Selenium exerts important biological functions through its presence in selenoproteins, he explained, and genetic variation in the major selenoproteins glutathione peroxidase 1 (GPX1) and selenoprotein P (SEPP1) has been associated with the risk of prostate cancer.

Interestingly, in the new study toenail selenium was associated with a reduced risk of advanced prostate cancer among smokers and former smokers, but not among never smokers; and the association was slightly more pronounced for men diagnosed at eight or more years of follow-up.

In the next analysis, Geybels said, this same population will be studied to analyze the association of common variation in GPX1 and SEPP1 with advanced prostate cancer.

Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.

Email:

Password Sent

Link to reset your password has been sent to specified email address.

Remember me

What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
computer.

To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.

What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.